Sage Journals: Discover world-class research

Abstract

Background:

Kratom (Mitragyna speciosa Korth) use has increased in Western countries, with a rising number of associated deaths. There is growing debate about the involvement of kratom in these events.

Aims:

This study details the characteristics of such fatalities and provides a ‘state-of-the-art’ review.

Methods:

UK cases were identified from mortality registers by searching with the terms ‘kratom’, ‘mitragynine’, etc. Databases and online media were searched using these terms and ‘death’, ‘fatal*’, ‘overdose’, ‘poisoning’, etc. to identify additional cases; details were obtained from relevant officials. Case characteristics were extracted into an Excel spreadsheet, and analysed employing descriptive statistics and thematic analysis.

Results:

Typical case characteristics (n = 156): male (80%), mean age 32.3 years, White (100%), drug abuse history (95%); reasons for use included self-medication, recreation, relaxation, bodybuilding, and avoiding positive drug tests. Mitragynine alone was identified/implicated in 23% of cases. Poly substance use was common (87%), typically controlled/recreational drugs, therapeutic drugs, and alcohol. Death cause(s) included toxic effects of kratom ± other substances; underlying health issues.

Conclusions:

These findings add substantially to the knowledge base on kratom-associated deaths; these need systematic, accurate recording. Kratom’s safety profile remains only partially understood; toxic and fatal levels require quantification.

Keywords

Mitragynine kratom cause of death toxicology characteristics

Get full access to this article

View all access options for this article.

References

Abayarathna

Jaehne

(2016) Electronic Vapor Liquid Composition and Method of Use. US Patent US 20160174603 A1, 23 June. Available at: https://www.google.com/patents/US20160174603 (accessed 15 May 2019).

Adkins

Boyer

McCurdy

(2011) Mitragyna speciosa, a psychoactive tree from Southeast Asia with opioid activity. Curr Top Med Chem 11: 1165–1175.

Administrative Committe of Substance Abuse Academic Network (2012) Size Estimation Regarding Substance Abuse in Thailand 2554. Thailand: Office of the Narcotics Control Board.

Ahmad

Aziz

(2012) Mitragyna speciosa use in the northern states of Malaysia: A cross-sectional study. J Ethnopharmacol 141: 446–450.

Anderson

Duffy

Harre

et al. (2014) Four Odd Cases in the Valley of the Sun. Abstract P-68 in Book of Abstracts of Society of Forensic Toxicologists (SOFT) 2014, 19–24 October 2014, DeVos Convention Center, Grand Rapids Michigan. Available at: http://www.soft-tox.org/files/meeting_abstracts/SOFT_2014_meeting_abstracts.pdf (accessed 15 May 2019).

Anwar

Law

Schier

(2016) Notes from the field: Kratom (Mitragyna speciosa) exposures reported to poison centers - United States, 2010–2015. MMWR Morb Mortal Wkly Rep 65: 748–749.

Assanangkornchai

Muekthong

Sam-Angsri

et al. (2007) The use of Mitragynine speciosa (‘Krathom’), an addictive plant, in Thailand. Subst Use Misuse 42: 2145–2157.

Azizi

Ismail

Mansor

(2013) Mitragyna speciosa korth leaves extracts induced the CYP450 catalyzed aminopyrine-N-demethylase (APND) and UDP-glucuronosyl transferase (UGT) activities in male Sprague-Dawley rat livers. Drug Metabol Drug Interact 28: 95–105.

Babu

McCurdy

Boyer

(2008) Opioid receptors and legal highs: Salvia divinorum and kratom. Clin Toxicol (Phila) 46: 146–152.

10.

Bäckstrom

Classon

Löwenhielm

et al. (2010) Krypton – ny, dödlig Internetdrog. Sedan oktober 2009 har nio unga personer dött i Sverige. [Krypton—new, deadly internet drug. Since October 2009 nine young people have died in Sweden]. Läkartidningen 107: 3196–3197.

11.

Baselt

(2017) Disposition of Toxic Drugs and Chemicals in Man. 11th ed. Seal Beach: Biomedical Publications.

12.

Bhattacharjee

(2016) Shawn Lucas Confirmed Dead: Found Lying on the Bathroom Floor. Morning News USA, 5 August. Available at: https://www.morningnewsusa.com/shawn-lucas-confirmed-dead-found-lying-on-the-bathroom-floor-did-democrats-kill-him-2394986.html (accessed 15 May 2019).

13.

Bishop-Freeman

Feaster

Beal

et al. (2016) Loperamide-related deaths in North Carolina. J Anal Toxicol 40: 677–686.

14.

Boyer

Babu

Adkins

et al. (2008) Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth). Addiction 103: 1048–1050.

15.

Brodwin

(2018) A ruling is imminent on the legality of a controversial drug that’s used to treat addiction - but some have called it a ‘dangerous opioid’. Business Insider UK, 17 November. Available at: http://uk.businessinsider.com/is-kratom-legal-government-regulators-decide-2018-11?r=US&IR=T (accessed 15 May 2019).

16.

Brower

(2015) Postmortem Analysis of Kratom (Mitragynine) in North Carolina. Presentation at Society of Forensic Toxicologists (SOFT) 2015, 13–18 October 2015, Hyatt Regency Hotel, Atlanta, Georgia.

17.

Brower

Hargrove

Winecker

(2015) Postmortem Analysis of Kratom (mitragynine) in North Carolina. Abstract S17 in Book of Abstracts of Society of Forensic Toxicologists (SOFT) 2015. 13–18 October 2015, Hyatt regency hotel, Atlanta, Georgia. Available at: http://www.soft-tox.org/files/meeting_abstracts/SOFT_2015_meeting_abstracts.pdf (accessed 15 May 2019).

18.

Brown

Lund

Murch

(2017) A botanical, phytochemical and ethnomedicinal review of the genus mitragyna korth: Implications for products sold as kratom. J Ethnopharmacol 18: 302–325.

19.

Bruno

(2016) 9 Investigates Kratom: Natural herb or deadly drug? WSOCTV, 10 March. Available at: http://www.wsoctv.com/news/9-investigates/9-investigates-kratom-natural-herb-or-deadly-drug/68821730 (accessed 15 May 2019).

20.

Burkill

Haniff

(1930) Malay village medicine. In: The Garden’s Bulletin Straits Settlement, Vol. 6. Singapore: Botanic Gardens, pp. 165–207.

21.

Carter

Wills

Cumpston

(2016) Abstract 25: Clinical effects of kratom use: A poison center observational study. NACCT Abstracts 2016. Clin Toxicol 54: 659–811.

22.

CBS Miami (2014) Tragic death moves Broward commissioner to ban addictive drug. CBS Miami, 8 October. Available at: http://miami.cbslocal.com/2014/10/08/tragic-death-moves-broward-commissioner-to-ban-addictive-drug/ (accessed 15 May 2019).

23.

Chang Rai Times (2012) Kratom leaf for drug cocktail adds to Thailand’s Woes. Chang Rai Times, 23 July. Available at: https://www.chiangraitimes.com/kratom-leaf-for-drug-cocktail-adds-to-thailands-woes.html (accessed 15 May 2019).

24.

Chemist and Druggist (1930) Kratom eaters. The Chemist and Druggist 112: 702.

25.

Chongrattanakon

Thepthien

Hong

(2017) Prevalence and psycho-social determinants of kratom (Mitragyna speciosa) juice cocktail consumption among youth in Surat Thani Province, Thailand. J Substance Use 23: 144–153.

26.

Cinosi

Martinotti

Simonato

et al. (2015) Following ‘the Roots’ of kratom (Mitragyna speciosa): The evolution of an enhancer from a traditional use to increase work and productivity in Southeast Asia to a recreational psychoactive drug in Western Countries. Biomed Res Int 2015: 968786.

27.

Corkery

(2008) UK drug-related mortality – issues in definition and classification. Drugs and Alcohol Today 8: 17–25.

28.

Corkery

(2011) Response to Commentaries on ‘Bundle of fun’ or ‘bunch of problems’? Case series of khat-related deaths in the UK. Drugs: Education, Prevention and Policy 18: 431–432.

29.

Corkery

Schifano

Oyefeso

et al. (2011a) Review of literature and information on ‘khat-related’ mortality: A call for recognition of the issue and further research. Ann Ist Super Sanitá 47: 445–464.

30.

Corkery

Schifano

Oyefeso

et al. (2011b) ‘Bundle of fun’ or ‘bunch of problems’? Case series of khat-related deaths in the UK. Drugs: Education, Prevention and Policy 18: 408–425.

31.

Daly

Willis

Small

et al. (2007) A hierarchy of evidence for assessing qualitative health research. J Clin Epidemiol 60: 43–49.

32.

Daud

Lajis

Ariff

et al. (2012) Toxic plants poisoning cases reported to National poison center (2006–2009). Poster 88. Annual meeting abstracts, 10th annual congress of Asia-Pacific association of medical toxicology, Penang, Malaysia. November 2011. J Med Toxicol 8: 192–237.

33.

Davidson

Rawat

Stojanovski

et al. (2019) Natural drugs, not so natural effects: Neonatal abstinence syndrome secondary to ‘kratom’. J Neonatal Perinatal Med 12: 109–112.

34.

Davis

(2018) Riverside man is charged in fentanyl sting. Los Angeles Times, 25 October. Available at: http://www.pressreader.com/usa/los-angeles-times/20181025/282321090993145 (accessed 15 May 2019).

35.

DEA (2016a) Schedules of controlled substances: Temporary placement of mitragynine and 7-hydroxymitragynine into schedule I: A proposed rule by the drug enforcement agency. Drug Enforcement Agency, US Department of Justice, 31 August. Available at: https://www.gpo.gov/fdsys/pkg/FR-2016-08-31/pdf/2016-20803.pdf (accessed 15 May 2019).

36.

DEA (2016b) Mitragynine and 7-hydroxymitragynine: Background information and evaluation of ‘three factor analysis’ (factors 4, 5 and 6) for temporary scheduling. Drug Enforcement Agency, US Department of Justice, 1 September. Available at: https://www.regulations.gov/contentStreamer?documentId=DEA-2016-0015-0004&contentType=pdf (accessed 15 May 2019).

37.

DEA (2016c) Withdrawal of notice of intent to temporarily place mitragynine and 7-hydroxymitragynine into schedule I: A proposed rule by the drug enforcement agency. Drug Enforcement Agency, US Department of Justice, 13 October. Available at: https://www.gpo.gov/fdsys/pkg/FR-2016-10-13/pdf/2016-24659.pdf (accessed on 15 May 2019).

38.

DHSC (2018) Introduction of medical examiners and reforms to death certification in England and Wales: Government response to consultation. London: Department of Health and Social Care. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/715224/death-certification-reforms-government-response.pdf (accessed 15 May 2019).

39.

Domingo

Roider

Stöver

et al. (2017) Mitragynine concentrations in two fatalities. Forensic Sci Int 271: e1–e7.

40.

Dorman

Wong

Khan

(2015) Cholestatic hepatitis from prolonged kratom use: A case report. Hepatology 61: 1086–1087.

41.

Drago

Lane

Kochav

et al. (2017) The harm in kratom. Oncologist. pii: theoncologist. 2017-0279.

42.

Dunn

Lindstrom

(2018) Family members question practices at Anyana-Kai following deaths of loved ones. Toledo Blade, 12 October. Available at: https://www.toledoblade.com/local/daily-log/2018/10/12/family-members-question-practices-at-west-toledo-anyana-kai-following-deaths-of-loved-ones/stories/20181003146 (accessed 15 May 2019).

43.

Eldridge

Foster

Wyble

(2018) Neonatal abstinence syndrome due to maternal kratom use. Pediatrics 142: pii: e20181839.

44.

European Monitoring Centre for Drugs and Drug Addiction, EMCDDA (2011) Online sales of new psychoactive substances / ‘legal highs’: summary of results from the 2011 multilingual snapshots. Briefing Paper. 15 November. Lisbon: European monitoring centre for drugs and drug addiction. Available at: http://www.emcdda.europa.eu/system/files/publications/650/SnapshotSummary_314798.pdf (accessed 15 May 2019).

45.

EMCDDA (2015a) Kratom (Mitragyna speciosa) Drug Profile. Available at: http://www.emcdda.europa.eu/publications/drug-profiles/kratom (accessed 15 May 2019).

46.

EMCDDA (2015b) New psychoactive substances in Europe. An update from the EU early warning system. Lisbon: European monitoring centre for drugs and drug addiction. Available at: http://www.emcdda.europa.eu/system/files/publications/65/TD0415135ENN.pdf (accessed 15 May 2019).

47.

FDA (2018a) CFSAN adverse event reporting system: Kratom deaths (December 1, 2017). U.S. Food and Drug Administration. Available at: https://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofFoods/CFSAN/CFSANFOIAElectronicReadingRoom/UCM588952.pdf (accessed 15 May 2019).

48.

FDA (2018b) FDA adverse event reporting system: Kratom deaths (February 6, 2018). U.S. Food and Drug Administration. Available at: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/CDERFOIAElectronicReadingRoom/UCM595575.pdf (accessed 15 May 2019).

49.

FDA (2018c) Kratom additional death adverse event reports. Available at: https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/cderfoiaelectronicreadingroom/ucm599611.pdf (accessed 15 May 2019).

50.

Fogarty

Papsun

Logan

(2018) Analysis of fentanyl and 18 novel fentanyl analogs and metabolites by LC-MS-MS, and report of fatalities associated with methoxyacetylfentanyl and cyclopropylfentanyl. J Anal Toxicol 42: 592–604.

51.

Forrester

(2013) Kratom exposures reported to Texas poison centers. J Addict Dis 32: 396–400.

52.

Frost

Deking

Neerman

(2012) A drug fatality involving kratom: A case report. Abstract S06 in book of abstracts of Society of Forensic Toxicologists (SOFT) 2012. 1–6 July 2012, Marriott Copley Place, Boston. Available at: http://www.soft-tox.org/files/meeting_abstracts/SOFT_2012_meeting_abstracts.pdf (accessed 15 May 2019).

53.

Fuenffinger

Ritchie

Ruth

et al. (2017) Evaluation of ion mobility spectrometry for the detection of mitragynine in kratom products. J Pharm Biomed Anal 134: 282–286.

54.

Fugelstad

Ramstedt

Thiblin

et al. (2017) Drug-related deaths: Statistics based on death certificates miss one-third of cases. Scand J Public Health. Epub ahead of print 1 December 2017. DOI: 10.1177/1403494817745187.

55.

Gershman

Timm

Frank

et al. (2019) Deaths in Colorado attributed to kratom. N Engl J Med 380: 97–98.

56.

Grant

Booth

(2009) A typology of reviews: An analysis of 14 review types and associated methodologies. Health Info Libr J 26: 91–108.

57.

Greenfield

(2015) What’s kratom? Parents claim the drug drove son to suicide. Yahoo News, 20 May. Available at: https://www.yahoo.com/news/whats-kratom-parents-speak-out-after-drug-drives-119458538452.html (accessed 15 May 2019).

58.

Griffin

3rd Daniels

Gardner

(2016) Do you get what you paid for? An examination of products advertised as kratom. J Psychoactive Drugs 48: 330–335.

59.

Griffiths

Gandhi

Olin

(2018) Possible kratom-induced hepatomegaly: A case report. J Am Pharm Assoc 58: 561–563.

60.

Grundmann

(2017) Patterns of kratom use and health impact in the US-results from an online survey. Drug Alcohol Depend 176: 63–70.

61.

Guddat

Görgens

Steinhart

et al. (2016) Mitragynine (Kratom) - monitoring in sports drug testing. Drug Test Anal 8: 1114–1118.

62.

Gunderson

Haughey

Ait-Daoud

et al. (2014) A survey of synthetic cannabinoid consumption by current cannabis users. Subst Abus 35: 184–189.

63.

Gutierrez

Cohn

(2018) Perceived risk of emerging recreational drugs: Impact of anecdotal and statistical evidence. J Drug Issues 48: 435–451.

64.

Haarer

(2018) Colorado coroners link kratom to at least 23 deaths since 2016. 9News, 13 November. Available at: https://www.9news.com/article/news/health/colorado-coroners-link-kratom-to-at-least-23-deaths-since-2016/73-614063305 (accessed 18 November 2018).

65.

Hanapi

Ismail

Mansor

(2013) Inhibitory effect of mitragynine on human cytochrome P450 enzyme activities. Pharmacognosy Res 5: 241–246.

66.

Hassan

Muzaimi

Navaratnam

et al. (2013) From kratom to mitragynine and its derivatives: Physiological and behavioural effects related to use, abuse, and addiction. Neurosci Biobehav Rev 37: 138–151.

67.

Hemby

McIntosh

Leon

et al. (2018) Abuse liability and therapeutic potential of the mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine. Addict Biol. Epub ahead of print 27 June 2018. DOI: 10.1111/adb.12639.

68.

Henningfield

Fant

Wang

(2018) The abuse potential of kratom according the 8 factors of the controlled substances act: Implications for regulation and research. Psychopharmacology (Berl) 235: 573–589.

69.

Hillebrand

Olszewski

Sedefov

(2010) Legal highs on the internet. Subst Use Misuse 45: 330–340.

70.

Holler

Vorce

McDonough-Bender

et al. (2011) A drug toxicity death involving propylhexedrine and mitragynine. J Anal Tox 35: 54–59.

71.

Home Office (2013) Circular 004/2013: Control of Synthetic Cannabinoids. London: Home office. Available at: https://www.gov.uk/government/publications/circular-0042013-control-of-synthetic-cannabinoids (accessed 15 May 2019).

72.

Hughes

(2019) Fatal combination of mitragynine and quetiapine: A case report with discussion of a potential herb-drug interaction. Forensic Sci Med Pathol 15: 110–113.

73.

Jaliawala

Abdo

Carlile

(2018) Kratom: A potential cause of acute respiratory distress syndrome. American thoracic society 2018 international conference D35. Drug-induced lung disease: Case reports. 23 May 2018, San Diego Convention Center. Am J Respir Crit Care Med 197: A6604. https://www.atsjournals.org/doi/abs/10.1164/ajrccm_conference.2018.197.1_MeetingAbstracts.A66042018.197.1_MeetingAbstracts.A6604

74.

Janchawee

Keawpradub

Chittrakarn

et al. (2007) A high-performance liquid chromatographic method for determination of mitragynine in serum and its application to a pharmacokinetic study in rats. Biomed Chromatogr 21: 176–183.

75.

Jones

McAninch

(2015) Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines. Am J Prev Med 49: 493–501.

76.

Kapp

Maurer

Auwärter

et al. (2011) Intrahepatic cholestasis following abuse of powdered kratom (Mitragyna speciosa). J Med Toxicol 7: 227–231.

77.

Karinen

Fosen

Rogde

et al. (2014) An accidental poisoning with mitragynine. Forensic Sci Int 245: e29–e32.

78.

Kikura-Hanajiri

Kawamura

Maruyama

et al. (2009) Simultaneous analysis of mitragynine, 7-hydroxymitragynine, and other alkaloids in the psychotropic plant ‘kratom’ (Mitragyna speciosa) by LC-ESI-MS. Forensic Toxicol 27: 67–74.

79.

King

Corkery

(2018) An index of fatal toxicity for new psychoactive substances. J Psychopharmacol 32: 793–801.

80.

Kruegel

Gassaway

Kapoor

et al. (2016) Synthetic and receptor signaling explorations of the mitragyna alkaloids: Mitragynine as an atypical molecular framework for opioid receptor modulators. J Am Chem Soc 138: 6754–6764.

81.

Kruegel

Grundmann

(2018) The medicinal chemistry and neuropharmacology of kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse. Neuropharmacology 134(Pt A): 108–120.

82.

Kronstrand

Roman

Thelander

et al. (2011) Unintentional fatal intoxications with mitragynine and O-desmethyltramadol from the herbal blend Krypton. J Anal Toxicol 35: 242–247.

83.

Kupferschmidt

(2011) Toxic hepatitis after kratom (Mitragyna sp.) consumption, abstract 39. Abstracts of the 2011 North American congress of clinical toxicology annual meeting, September 21–26, Washington, DC, USA. Clin Toxicol 49: 532.

84.

LaBryer

Sharma

Chaudhari

et al. (2018) Kratom, an emerging drug of abuse, raises prolactin and causes secondary hypogonadism: case report. J Investig Med High Impact Case Rep 6: 2324709618765022.

85.

LawPlus Ltd (2019) Thai law on medical use of cannabis. Tweet, 23 April. Available at: https://www.facebook.com/permalink.php?id=1018177951557734&story_fbid=2672446539464192 (accessed 16 May 2019).

86.

Lesiak

Cody

Dane

et al. (2014) Rapid detection by direct analysis in real time-mass spectrometry (DART-MS) of psychoactive plant drugs of abuse: The case of mitragyna speciosa aka ‘kratom’. Forensic Sci Int 242: 210–218.

87.

LGC (2018) Government Chemist Review 2017. LGC: Teddington, Middlesex. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/739631/Government_Chemist_Review_2017.pdf (accessed 15 May 2019).

88.

Liss

Halcomb

Schwarz

et al. (2016) Abstract 28: Spontaneous intraparenchymal cerebral hemorrhage in a patient taking mitragyna speciosa (kratom). NIACCT abstracts 2016. Clin Toxicol 54: 659–811.

89.

Logan

(2016a) Designer drug update summer 2016 webinar. NMS Labs, August. Available at: https://ndews.umd.edu/sites/ndews.umd.edu/files/nms_labs_nps_webinar_august_2016.pdf (accessed 15 May 2019).

90.

Logan

(2016b) NPS: Dangerous & difficult to detect. NMS Labs, August. Available at: http://www.nmslabs.com/uploads/PDF/Designer%20Drugs_Novel%20Psychoactive%20Substances%20(NPS)%20Trends%20Data%202016.pdf (accessed 29 April 2017).

91.

Wei

et al. (2014) Evaluation of the cardiotoxicity of mitragynine and its analogues using human induced pluripotent stem cell-derived cardiomyocytes. PLoS One 9: e115648.

92.

Luce

Smith

(2018) Death certification reform in England. BMJ 361: k2668.

93.

Lydecker

Sharma

McCurdy

et al. (2016) Suspected adulteration of commercial kratom products with 7-Hydroxymitragynine. J Med Toxicol 12: 341–349.

94.

Lydecker

Zuckerman

Hack

et al. (2017) Intravenous kratom use in a patient with opioid dependence. J Toxicol Pharmacol 1: 003.

95.

Lystra

(2013) Coroner: Role of kratom in longview’s mom’s death undetermined. The Daily News, 7 May. Available at: http://tdn.com/news/local/coroner-role-of-kratom-in-longview-mom-s-death-undetermined/article_0822689c-b74e-11e2-a636-0019bb2963f4.html (accessed 8 May 2016).

96.

Mackay

Abrahams

(2018) Novel case of maternal and neonatal kratom dependence and withdrawal. Can Fam Physician 64: 121–122.

97.

Main

(2018) Kratom, health supplement targeted by FDA, linked to 9 deaths in Cook County. Chicago Sun Times, 5 March. Available at: https://chicago.suntimes.com/business/kratom-health-supplement-targeted-by-fda-linked-to-8-deaths-in-cook-county/ (accessed 15 May 2019).

98.

Martinotti

Cinosi

Santacroce

et al. (2017) Substance-related psychopathology and aggressiveness in a nightlife holiday resort: Results from a pilot study in a psychiatric inpatient unit in Ibiza. Hum Psychopharmacol 32: e2586.

99.

Maruyama

Kawamura

Kikura-Hanajiri

et al. (2009) The botanical origin of kratom (Mitragyna speciosa; Rubiaceae) available as abused drugs in the Japanese markets. J Nat Med 63: 340–344.

100.

Matsumoto

Mizowaki

Suchitra

et al. (1996) Central antinoceptive effects of mitragynine in mice: Contributions from noradrenergic and serotonergic systems. Eur J Pharmacol 317: 75–81.

101.

Matsumoto

Horie

Ishikawa

et al. (2004) Antinociceptive effect of 7-hydroxymitragynine in mice: Discovery of an orally active opioid analgesic from the Thai medicinal herb mitragyna speciosa. Life Sci 74: 2143–2155.

102.

McBride

(2016) DNC process server Shawn Lucas cause of death released. Heavy.com, 1 November. Available at: http://speciosa.org/dnc-process-server-shawn-lucas-cause-of-death-released-_-kratom-is-one-of-the-reported-substances-in-his-system/ (accessed 15 May 2019).

103.

McIntyre

Tochta

Stolberg

et al. (2015) Mitragynine ‘Kratom’ related fatality: A case report with post-mortem concentrations. J Anal Toxicol 39: 152–156.

104.

McWhirter

Morris

(2010) A case report of inpatient detoxification after kratom (Mitragyna speciosa) dependence. Eur Addict Res 16: 229–231.

105.

Murthy

Clark

(2019) An unusual cause for neonatal abstinence syndrome. Paediatr Child Health 24: 12–14.

106.

Neerman

Frost

Deking

(2013) A drug fatality involving kratom. J Forensic Sci 58(Suppl 1): S278–S279.

107.

Nelsen

Lapoint

Hodgman

et al. (2010) Seizure and coma following kratom (Mitragynina speciosa korth) exposure. J Med Toxicol 6: 424–426.

108.

NIDA (2019) DrugFacts – What is kratom? Rockville, MD: National Institute on Drug Abuse. Available at: https://www.drugabuse.gov/publications/drugfacts/kratom (accessed 15 May 2019).

109.

O’Halloran

(2011) Coroner warns on using herbal tea with other substances. Irish Times, 9 June. Available at: http://www.irishtimes.com/news/coroner-warns-on-using-herbal-tea-with-other-substances-1.591290. (accessed 15 April 2019).

110.

O’Malley Olsen

O’Donnell

Mattson

et al. (2019) Notes from the field: Unintentional drug overdose deaths with kratom detected – 27 States, July 2016 – December 2017. MMWR Morb Mortal Wkly Rep 68: 326–327.

111.

Orio

Alexandru

Cravotto

et al. (2012) UAE, MAE, SFE-CO2 and classical methods for the extraction of mitragyna speciosa leaves. Ultrason Sonochem 19: 591–595.

112.

Pantano

Tittarelli

Mannocchi

et al. (2016) Hepatotoxicity induced by ‘the 3Ks’: Kava, kratom and khat. Int J Mol Sci 17: 580.

113.

Parthasarathy

Ramanathan

Ismail

et al. (2010) Determination of mitragynine in plasma with solid-phase extraction and rapid HPLC-UV analysis, and its application to a pharmacokinetic study in rat. Anal Bioanal Chem 397: 2023–2030.

114.

Pathak

Hahn

Cabellon

et al. (2014) Adult respiratory distress syndrome secondary to the use of herbal drug kratom, in proceedings of the American thoracic society international conference abstracts, San Diego, Calif, USA, May 2014. Am J Respiratory Critical Care Med 10. Available at: http://www.atsjournals.org/doi/book/10.1164/ajrccm-conference.2014 (accessed 15 May 2019).

115.

Perno

(2018) Synthetic drugs & emerging drug trends. Presentation. San Diego: Camp Pendleton. Available at: http://www.mccscp.com/mccscp/wp-content/uploads/2018/05/camp-pendleton-1.5-hour-synthetic-and-opioids-ppy-10-apr-18.pdf (accessed 15 May 2019).

116.

Perrone

Helgesen

Fischer

(2013) United States drug prohibition and legal highs: How drug testing may lead cannabis users to spice. Drugs: Education, Prevention and Policy 20: 216–224.

117.

Petersson

(2010) ‘Nätdrogen tog min son’ [‘Web-drug took my son’]. Aftonbladet, 14 April. Available at: http://www.aftonbladet.se/nyheter/article12274542.ab (accessed 15 May 2019).

118.

Philipp

Meyer

Wissenbach

et al. (2011) Monitoring of kratom or krypton intake in urine using GC-MS in clinical and forensic toxicology. Anal Bioanal Chem 400: 127–135.

119.

Poklis

Wolf

II CE

Peace

(2017) Ethanol concentration in 56 refillable electronic cigarettes liquid formulations determined by headspace gas chromatography with flame ionization detector (HS-GC-FID). Drug Test Anal 9: 1637–1640.

120.

Ponglux

Wongseripipatana

Takayama

et al. (1994) A new indole alkaloid, 7 alpha-hydroxy-7H-mitragynine, from mitragyna speciosa in Thailand. Planta Med 60: 580–581.

121.

Post

Spiller

Chounthirath

et al. (2019) Kratom exposures reported to United States poison control centers: 2011–2017. Clin Toxicol (Phila). Epub ahead of print 20 Feb 2019.

122.

Prozialeck

(2016) Update on the pharmacology and legal status of kratom. J Am Osteopath Assoc 116: 802–809.

123.

Prozialeck

Jivan

Andurkar

(2012) Pharmacology of kratom: An emerging botanical agent with stimulant, analgesic and opioid-like effects. J Am Osteopath Assoc 112: 792–799.

124.

Prutipanlai

Botpiboon

Janchawee

et al. (2017) Solid phase extraction method for determination of mitragynine in urine and its application to mitragynine excretion study in rats receiving caffeine. Trp J Pharmaceut Research 16: 1675–1682.

125.

Raj

(2017) Malaysia lacks statistics on fatal drug overdoses. The Malay Mail Online, 6 June. Available at: https://sg.news.yahoo.com/malaysia-lacks-statistics-fatal-drug-overdoses-232300605.html (accessed 15 May 2019).

126.

Ramoo

Gary

Peterson

(2017) P187. A death involving mitragynine (Kratom). In: Society of Forensic Toxicologists (SOFT) Annual Meeting, 9–14 September 2017, Boca Raton, Florida Conference Abstracts. Available at: http://www.soft-tox.org/files/meeting-abstracts/SOFT_2017_meeting_abstracts.pdf (accessed 15 May 2019).

127.

Riverso

Change

Soldevila-Pico

et al. (2018) Histologic characterization of kratom use–associated liver injury. Gastroenterol Res 11: 79–82.

128.

Roche

Hart

Sangali

et al. (2008) Kratom: A case of a legal high. Abstract 41. Abstracts of the 2008 North American congress of clinical toxicology annual meeting, September 11–16, 2008, Toronto, Canada. Clin Tox 46: 598.

129.

Rosenbaum

Carreiro

Babu

(2012) Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, salvia divinorum, methoxetamine, and piperazines. J Med Toxicol 8: 15–32.

130.

Sabetghadam

Navaratnam

Mansor

(2013) Dose–response relationship, acute toxicity, and therapeutic index between the alkaloid extract of mitragyna speciosa and its main active compound mitragynine in mice. Drug Development Research 74: 23–30.

131.

Saingam

Assanangkornchai

Geater

et al. (2013) Pattern and consequences of krathom (Mitragyna speciosa Korth.) use among male villagers in southern Thailand: A qualitative study. Intl J Drug Policy 24: 351–358.

132.

Sakulsaengprapha

Peonim

Worasuwanarak

(2018) Trends of homicide deaths in central Bangkok, Thailand: A 5-year retrospective study. Egyptian J Forensic Sciences 8: 14.

133.

Santacroce

Ruiz Bennasar

Sancho Jaraiz

et al. (2017) A matter of life and death: Substance-caused and substance-related fatalities in Ibiza in 2015. Hum Psychopharmacol 32: e2592.

134.

Sattaburuth

(2018) Medical cannabis, kratom bill passed by NLA. Bangkok Post, 25 December. Available at: https://www.bangkokpost.com/news/general/1600566/medical-cannabis-kratom-bill-passed-by-nla (accessed 15 May 2019).

135.

Sayre

Toklu

et al. (2017) Case reports, case series – from clinical practice to evidence-based medicine in graduate medical education. Cureus 9: e1546.

136.

Schifano

Corkery

Deluca

et al. (2006) Ecstasy (MDMA, MDA, MDEA, MBDB) consumption, seizures, related offences, prices, dosage levels and deaths in the UK (1994–2003). J Psychopharmacol 20: 456–463.

137.

Schifano

Orsolini

Papanti

et al. (2015) Novel psychoactive substances of interest for psychiatry. World Psychiatry 14: 15–26.

138.

Schmidt

Sharma

Schifano

et al. (2011) ‘Legal highs’ on the net-evaluation of UK-based websites, products and product information. Forensic Sci Int 206: 92–97.

139.

Scott

Yeakel

Logan

(2014) Identification of mitragynine and O-desmethyltramadol in kratom and legal high products sold online. Drug Test Anal 6: 959–963.

140.

Shai

(1994) Problems of accuracy in official statistics on drug-related deaths. Int J Addict 29: 1801–1811.

141.

Sheleg

Collins

(2011) A coincidence of addiction to ‘kratom’ and severe primary hypothyroidism. J Addict Med 5: 300–301.

142.

Shellard

Houghton

Resha

(1978) The mitragyna species of Asia: Part XXXII. The distribution of alkaloids in young plants of mitragyna speciosa korth grown from seed obtained from Thailand. Planta Med 34: 253–263.

143.

Singh

Müller

Vicknasingam

(2014) Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users. Drug Alcohol Depend 139: 132–137.

144.

Singh

Müller

Vicknasingam

et al. (2015) Social functioning of kratom (mitragyna speciosa) users in Malaysia. J Psychoactive Drugs 47: 25–31.

145.

Singh

Narayanan

Vicknasingam

(2016) Traditional and non-traditional uses of mitragynine (kratom): A survey of the literature. Brain Res Bull 126: 41–46.

146.

Singh

Narayanan

Müller

et al. (2019) Long-term cognitive effects of kratom (mitragyna speciosa korth.) use. J Psychoactive Drugs 51: 19–27.

147.

Slavova

O’Brien

Creppage

et al. (2015) Drug overdose deaths: Let’s get specific. Public Health Rep 130: 339–342.

148.

Smith

Lawson

(2017) Prevalence and motivations for kratom use in a sample of substance users enrolled in a residential treatment program. Drug Alcohol Depend 180: 340–348.

149.

Smith

Lin

Hwang

et al. (2019) Chem Res Toxicol 32: 113–121.

150.

Smith

(2018) Father tells cautionary tale of kratom. UCHealth, 13 November. Available at: https://www.uchealth.org/today/2018/11/13/father-tells-cautionary-tale-of-kratom/ (accessed 15 May 2019).

151.

Stanciu

Gnanasegaram

Ahmed

et al. (2019) Kratom withdrawal: A systematic review with case series. J Psychoactive Drugs 51:12–18.

152.

Streete

(2014) Mitragyna: Should we be concerned? Oral presentation. 2014 UKIAFT (United Kingdom and Ireland Association of Forensic Toxicologists) summer meeting. Leicester University. 28–29 August. Available at: http://www.ukiaft.co.uk/image/catalog/Meetings/Leicester-2014-Meeting-Agenda.pdf (accessed 15 May 2019).

153.

Suwanlert

(1975) A study of kratom eaters in Thailand. Bull Narc 27: 21–27.

154.

Swetlitz

(2018) HHS recommended that the DEA make kratom a schedule I drug, like LSD or heroin. STAT, 9 November. Available at: https://www.statnews.com/2018/11/09/hhs-recommended-dea-ban-kratom-documents-show/ (accessed 15 May 2019).

155.

Swogger

Hart

Erowid

et al. (2015) Experiences of kratom users: A qualitative analysis. J Psychoactive Drugs 47: 360–367.

156.

Takayama

(2004) Chemistry and pharmacology of analgesic indole alkaloids from the rubiaceous plant, Mitragyna speciose. Chem Pharm Bull (Tokyo) 52: 916–928.

157.

Tanguay

(2011) Kratom in Thailand, decriminalisation and community control? Series on legislative reform of drug policies, No. 13. Transnational Institute. International Drug Policy Consortium. Available at: http://speciosa.org/wp-content/uploads/2016/03/Transitional-Institutes-Analysis-Legislative-Reform-of-Drug-Policies-Addresses-Kratom-Law-Reform-in-Thailand.pdf (accessed 15 May 2019).

158.

Tatum

Hasan

Coonan

et al. (2018) Recurrent seizures from chronic kratom use, an atypical herbal opioid. Epilepsy Behav Case Rep 10: 18–20.

159.

Thaikla

Pinyopornpanish

Jiraporncharoen

et al. (2018) Cannabis and kratom online information in Thailand: Facebook trends 2015–2016. Subst Abuse Treat Prev Policy 13: 15.

160.

thewatershed.com (2014) Kratom addiction claimed the life of Ian Mautner, 29 September. Available at: https://www.thewatershed.com/blog/kratom-addiction-claimed-the-life-of-ian-mautner/ (accessed 29 April 2017).

161.

Toler

(2016) Senate passes bill regulating sale of kratom. Richmond County Daily Journal, 27 June. Available at: http://yourdailyjournal.com/news/local-news-5/38753/senate-passes-bill-regulating-sale-of-kratom (accessed 15 May 2019).

162.

Trakulsrichai

Sathirakul

Auparakkitanon

et al. (2015) Pharmacokinetics of mitragynine in man. Drug Des Devel Ther 9: 2421–2429.

163.

Trakulsrichai

Tongpo

Sriapha

et al. (2013) Kratom abuse in Ramathibodi poison center, Thailand: A five-year experience. J Psychoactive Drugs 45: 404–408.

164.

Tungtananuwat

Lawanprasert

(2010) Fatal 4x100; Home-made kratom juice cocktail. J Health Res 24: 43–47.

165.

UNODC (2014) Global Synthetic Drugs Assessment – Amphetamine-Type Stimulants and New Psychoactive Substances. Vienna: United Nations Office on Drugs and Crime. Available at: https://www.unodc.org/documents/scientific/2014_Global_Synthetic_Drugs_Assessment_web.pdf (accessed 15 May 2019).

166.

UNODC (2018) World drug report 2018. Volume 2: Global overview of drug demand and supply - Latest trends, cross-cutting issues. Vienna; United Nations Office on Drugs and Crime. Available at: https://www.unodc.org/wdr2018/prelaunch/WDR18_Booklet_2_GLOBAL.pdf (accessed 15 May 2019).

167.

Váradi

Marrone

Palmer

et al. (2016) Mitragynine/corynantheidine pseudoindoxyls as opioid analgesics with Mu agonism and delta antagonism, which do not recruit β-arrestin-2. J Med Chem 59: 8381–8397.

168.

Vigil

(2014) Denver family warns others about dangers of legal herbal stimulant. Kdvr.com, 1 March. Available at: http://kdvr.com/2014/03/01/denver-family-warns-others-about-dangers-of-legal-herbal-stimulant/ (accessed 8 May 2016).

169.

Vlahos

(2018) Nick in the AM: Death related to Southeast Asian drug is first in Peoria County. Journal Star, 19 November. Available at: https://www.pjstar.com/news/20181119/nick-in-am-death-related-to-southeast-asian-drug-is-first-in-peoria-county (accessed 25 November 2018).

170.

WADA (2015) The 2016 monitoring program. Montreal, Canada: World Anti-Doping Agency. Available at: https://www.wada-ama.org/sites/default/files/resources/files/wada-2016-monitoring-program-en.pdf (accessed 15 May 2019).

171.

Wang

Walker

(2018) Fatal mitragynine-associated toxicity in Canada: A case report and review of the literature. Acad Forensic Pathol 8: 340–346.

172.

Warner

Kaufman

Grundmann

(2016) The pharmacology and toxicology of kratom: From traditional herb to drug of abuse. Int J Legal Med 130: 127–138.

173.

Whigham

(2014a) Boynton beach I-95 suicide victim had kratom in his system, tests confirm. Palmbeachpost.com, 1 October. Available at: http://www.palmbeachpost.com/news/news/local/i-95-suicide-victim-had-kratom-in-his-system/nhZX9/ (accessed 8 May 2016).

174.

Whigham

(2014b) Delray beach vigil held to support families torn apart by addiction. Palbeachpost.com, 1 September. Available at: http://www.palmbeachpost.com/news/news/local/candlelight-vigil-held-to-support-families-torn-ap/nhDRf/ (accessed 8 May 2016).

175.

Wing

(2018a) Ohio pushes kratom ban with disputed claims about deaths, use trends. Huffington Post, 16 October. Available at: https://www.huffingtonpost.co.uk/entry/ohio-kratom-ban_us_5bbe06cee4b0876edaa45ab6 ( accessed 15 May 2019).

176.

Wing

(2018b) Peoria County coroner recently reported its first kratom-related death. Twitter Thread, 21 November. https://twitter.com/nickpwing/status/1065269846580056064 (accessed 15 May 2019).

177.

Wonguppa

Kanato

(2017) The prevalence and associated factors of new psychoactive substance use: A 2016 Thailand national household survey. Addict Behav Rep 7: 111–115.

178.

Wooten

(2016) State crime lab says kratom linked to 3 deaths in Arkansas. Nwa.com, 17 February. Available at: http://www.nwahomepage.com/news/state-crime-lab-says-kratom-linked-to-3-deaths-in-arkansas (accessed 8 May 2016).

179.

Wright

(2018) Suspected driving under the influence case involving mitragynine. J Anal Toxicol 42: e65–e60.

180.

Yue

Kopajtic

Katz

(2018) Abuse liability of mitragynine assessed with a self-administration procedure in rats. Psychopharmacology (Berl) 235: 2823–2829.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

1.26 MB

Characteristics of deaths associated with kratom use

Abstract

Background:

Aims:

Methods:

Results:

Conclusions:

Keywords

Get full access to this article

References

Supplementary Material